Boston Scientific Announces Canadian Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death

    NATICK, Mass., Oct. 24 /CNW/ -- Boston Scientific Corporation (NYSE:   BSX)
today announced regulatory approval in Canada for its COGNIS(TM) cardiac
resynchronization therapy defibrillator (CRT-D) and TELIGEN(TM) implantable
cardioverter defibrillator (ICD).  These devices represent entirely new
platforms to treat heart failure and sudden cardiac death and are the result
of a multi-year research and development effort to provide physicians enhanced
clinical options for their patients.
    When choosing a high-energy device, physicians often must make trade-offs
among device size, battery longevity and features.  The COGNIS CRT-D and the
TELIGEN ICD are designed to eliminate those compromises.  They are the world's
smallest and thinnest high-energy devices at 32.5 cc and 31.5 cc respectively,
while less than 10 mm thick.  Both devices offer innovative features based on
significant engineering advances, including extended battery longevity,
self-correcting software and improved programming technology.
    "Our CRM team is clearly focused on delivering therapy systems that meet
clinician needs for safety, reliability and better patient outcomes," said
Fred Colen, President, Boston Scientific Cardiac Rhythm Management.  "We are
very pleased with the positive customer response to COGNIS and TELIGEN since
the U.S. launch in August and look forward to a successful launch in Canada."

    Key features of the COGNIS CRT-D include:

    -- SmartDelay(TM): quickly proposes programmable device settings, which
       enables physicians to tailor individualized pacing therapy for their
    -- Bi-V Trigger: helps physicians manage heart failure patients with
       frequent atrial arrhythmias
    -- Electronic Repositioning(TM): provides physicians with six
       configurations for stimulating the left side of the heart even after
       implant, which may help avoid an additional surgical procedure

    Key features of the TELIGEN ICD include:

    -- Thinnest device available in the world, designed with patient comfort
       in mind
    -- Reverse Mode Switch(TM): designed to eliminate unnecessary ventricular
    -- Quick Convert(TM): provides the ability for patients to receive pacing
       therapy for ventricular tachycardias

    Both COGNIS and TELIGEN also offer SafetyCore(TM), a feature that in the
unlikely event of a system error provides lifesaving shock therapy and basic
pacing functionality.
    Boston Scientific is a worldwide developer, manufacturer and marketer of
medical devices whose products are used in a broad range of interventional
medical specialties.  For more information, please visit:

    Cautionary Statement Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning
of Section 21E of the Securities Exchange Act of 1934.  Forward-looking
statements may be identified by words like "anticipate," "expect," "project,"
"believe," "plan," "estimate," "intend" and similar words.  These
forward-looking statements are based on our beliefs, assumptions and estimates
using information available to us at the time and are not intended to be
guarantees of future events or performance.  These forward-looking statements
include, among other things, statements regarding our product performance,
regulatory approval of our products, new product launches, competitive
offerings, our growth strategy, and our market position.  If our underlying
assumptions turn out to be incorrect, or if certain risks or uncertainties
materialize, actual results could vary materially from the expectations and
projections expressed or implied by our forward-looking statements.  These
factors, in some cases, have affected and in the future (together with other
factors) could affect our ability to implement our business strategy and may
cause actual results to differ materially from those contemplated by the
statements expressed in this press release.  As a result, readers are
cautioned not to place undue reliance on any of our forward-looking
    Factors that may cause such differences include, among other things:
future economic, competitive, reimbursement and regulatory conditions; new
product introductions; demographic trends; intellectual property; litigation;
financial market conditions; and, future business decisions made by us and our
competitors.  All of these factors are difficult or impossible to predict
accurately and many of them are beyond our control.  For a further list and
description of these and other important risks and uncertainties that may
affect our future operations, see Part I, Item 1A - Risk Factors in our most
recent Annual Report on Form 10-K filed with the Securities and Exchange
Commission, which we may update in Part II, Item 1A - Risk Factors in
Quarterly Reports on Form 10-Q we have filed or will file thereafter.  We
disclaim any intention or obligation to publicly update or revise any
forward-looking statements to reflect any change in our expectations or in
events, conditions, or circumstances on which those expectations may be based,
or that may affect the likelihood that actual results will differ from those
contained in the forward-looking statements.  This cautionary statement is
applicable to all forward-looking statements contained in this document.

    CONTACT:  Paul Donovan
              508-650-8541 (office)
              508-667-5165 (mobile)
              Media Relations
              Boston Scientific Corporation

              Larry Neumann
              508-650-8696 (office)
              Investor Relations
              Boston Scientific Corporation


For further information:

For further information: Media Relations, Paul Donovan, +1-508-650-8541
(office) or +1-508-667-5165 (mobile), or Investor Relations, Larry Neumann,
+1-508-650-8696, both of Boston Scientific Corporation; Web Site:

Organization Profile

Boston Scientific Corporation

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890